Security
Structure Therapeutics Inc. American Depositary Shares · GPCR
GPCRNASDAQotherCurrentCIK 1888886Updated Oct 6, 2026
Name history
ShouTi Inc. · through May 13, 2022
GPCR price & chart
Loading TradingView…
NASDAQ:GPCR on TradingView ↗About the company
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
In the news
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 832,159,000Source | 933,217,000Source | 1,425,415,000Source | 816,443,000Source | 947,029,000Source | 1,508,124,000Source | 866,549,000Source | 457,225,000Source | 1,583,918,000Source | 903,330,000Source | 482,017,000Source | 97,845,000Source |
| Property, Plant and Equipment, NetUSD | 4,675,000Source | 3,735,000Source | 6,332,000Source | 3,459,000Source | 3,315,000Source | 6,365,000Source | 3,518,000Source | 3,120,000Source | 6,653,000Source | 3,478,000Source | 3,228,000Source | 1,031,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 102,912,000Source | 172,130,000Source | 272,638,000Source | 147,024,000Source | 381,627,000Source | 316,168,000Source | 152,123,000Source | 97,832,000Source | 799,623,000Source | 169,510,000Source | 129,792,000Source | 26,091,000Source |
| Assets, CurrentUSD | 814,022,000Source | 923,651,000Source | 1,372,028,000Source | 799,298,000Source | 937,621,000Source | 1,490,598,000Source | 849,622,000Source | 449,360,000Source | 1,570,303,000Source | 891,211,000Source | 473,608,000Source | 93,089,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,979,000Source | 8,365,000Source | 29,370,000Source | 12,802,000Source | 10,502,000Source | 32,094,000Source | 12,740,000Source | 12,911,000Source | 24,106,000Source | 7,693,000Source | 6,285,000Source | 2,248,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,863,000Source | 4,009,000Source | 6,060,000Source | 7,484,000Source | 4,267,000Source | 5,606,000Source | 7,313,000Source | 4,698,000Source | 6,245,000Source | 3,535,000Source | 5,136,000Source | 262,000Source |
| Other Assets, NoncurrentUSD | 6,599,000Source | 1,822,000Source | 40,995,000Source | 6,202,000Source | 1,826,000Source | 5,555,000Source | 6,096,000Source | 47,000Source | 717,000Source | 5,106,000Source | 45,000Source | 3,463,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 62,140,000Source | 36,416,000Source | 71,011,000Source | 44,362,000Source | 25,997,000Source | 61,030,000Source | 41,911,000Source | 27,407,000Source | 67,541,000Source | 38,487,000Source | 29,051,000Source | 13,010,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 18,000Source | 17,000Source | 21,000Source | 17,000Source | 17,000Source | 21,000Source | 17,000Source | 14,000Source | 21,000Source | 17,000Source | 14,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 1,272,480,000Source | 1,186,564,000Source | 2,010,255,000Source | 1,209,294,000Source | 1,180,144,000Source | 1,995,536,000Source | 1,199,737,000Source | 662,502,000Source | 1,985,602,000Source | 1,193,010,000Source | 659,003,000Source | 1,921,000Source |
| Retained Earnings (Accumulated Deficit)USD | -503,304,000Source | -292,619,000Source | -652,427,000Source | -437,592,000Source | -258,642,000Source | -546,268,000Source | -375,931,000Source | -232,608,000Source | -470,300,000Source | -329,098,000Source | -206,572,000Source | -116,952,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 825,000Source | 2,839,000Source | -3,445,000Source | 362,000Source | -487,000Source | -2,195,000Source | 815,000Source | -90,000Source | 1,054,000Source | 914,000Source | 521,000Source | -110,000Source |
| Stockholders' Equity Attributable to ParentUSD | 770,019,000Source | 896,801,000Source | 1,354,404,000Source | 772,081,000Source | 921,032,000Source | 1,447,094,000Source | 824,638,000Source | 429,818,000Source | 1,516,377,000Source | 864,843,000Source | 452,966,000Source | -115,140,000Source |
| Liabilities and EquityUSD | 832,159,000Source | 933,217,000Source | 1,425,415,000Source | 816,443,000Source | 947,029,000Source | 1,508,124,000Source | 866,549,000Source | 457,225,000Source | 1,583,918,000Source | 903,330,000Source | 482,017,000Source | 97,845,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 57,527,000Source | 33,434,000Source | 66,113,000Source | 39,033,000Source | 22,659,000Source | 56,984,000Source | 36,487,000Source | 23,586,000Source | 63,285,000Source | 36,021,000Source | 24,740,000Source | 13,010,000Source |
| Operating Lease, Liability, CurrentUSD | 2,802,000Source | 1,712,000Source | 2,595,000Source | 2,664,000Source | 1,629,000Source | 2,609,000Source | 2,471,000Source | 1,600,000Source | 2,878,000Source | 1,698,000Source | 1,440,000Source | 260,000Source |
| Accounts Payable, CurrentUSD | 17,796,000Source | 8,447,000Source | 11,131,000Source | 8,990,000Source | 2,209,000Source | 7,822,000Source | 8,710,000Source | 6,538,000Source | 13,864,000Source | 8,024,000Source | 4,742,000Source | 6,009,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,288,000Source | 2,673,000Source | 3,633,000Source | 5,012,000Source | 3,045,000Source | 3,183,000Source | 5,116,000Source | 3,525,000Source | 3,609,000Source | 2,164,000Source | 4,013,000Source | — |
| Other Liabilities, NoncurrentUSD | 325,000Source | 309,000Source | 1,265,000Source | 317,000Source | 293,000Source | 863,000Source | 308,000Source | 296,000Source | 647,000Source | 302,000Source | 298,000Source | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 799,000,000Source | 915,300,000Source | 1,342,700,000Source | 786,500,000Source | 927,100,000Source | 1,458,500,000Source | 836,900,000Source | 436,400,000Source | 1,446,200,000Source | 883,500,000Source | 467,300,000Source | — |
| Short-term InvestmentsUSD | 696,131,000Source | 743,156,000Source | 1,070,020,000Source | 639,472,000Source | 545,492,000Source | 1,142,336,000Source | 684,759,000Source | 338,617,000Source | 646,574,000Source | 714,008,000Source | 337,531,000Source | 64,750,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -75,968,000Source | -46,833,000Source | -141,202,000Source | -122,526,000Source | -89,620,000Source | -51,321,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 11,639,000Source | 5,918,000Source | 28,991,000Source | 18,794,000Source | 8,191,000Source | 2,514,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -4,967,000Source | 686,000Source | 4,765,000Source | 3,307,000Source | -860,000Source | 2,153,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 15,234,000Source | -52,229,000Source | -222,199,000Source | -116,636,000Source | -79,488,000Source | -46,120,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -496,947,000Source | 34,033,000Source | 89,796,000Source | -358,909,000Source | -268,342,000Source | -62,108,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,182,000Source | 314,000Source | 3,614,000Source | 1,290,000Source | 2,167,000Source | 155,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 2,574,000Source | 156,000Source | 618,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,742,000Source | 809,000Source | 762,516,000Source | 515,263,000Source | 451,531,000Source | 29,014,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -483,455,000Source | -17,387,000Source | 630,113,000Source | 39,718,000Source | 103,701,000Source | -79,214,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 102,912,000Source | 172,130,000Source | 272,638,000Source | 147,024,000Source | 316,168,000Source | 152,123,000Source | 799,623,000Source | 169,510,000Source | 129,792,000Source | 26,091,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 634,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,495,000Source | 6,023,000Source | 12,634,000Source | 7,509,000Source | 11,639,000Source | 5,918,000Source | 28,991,000Source | 18,794,000Source | 8,191,000Source | 2,514,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | — | — | — | — | 10,000Source | — | 345,000Source | 4,000Source | 21,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 799,000,000Source | 915,300,000Source | 1,342,700,000Source | 786,500,000Source | 1,458,500,000Source | 836,900,000Source | 1,446,200,000Source | 883,500,000Source | 467,300,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 576,000Source | 274,000Source | 1,333,000Source | 992,000Source | 295,000Source | 277,000Source |
| General and Administrative ExpenseUSD | — | — | 14,798,000Source | 13,238,000Source | 18,573,000Source | 15,741,000Source | 22,872,000Source | 13,444,000Source | 61,554,000Source | 49,414,000Source | 32,672,000Source | 16,368,000Source |
| Income Tax Expense (Benefit)USD | — | — | 108,000Source | 92,000Source | 234,000Source | 139,000Source | 190,000Source | 98,000Source | 515,000Source | 310,000Source | 236,000Source | 17,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -65,712,000Source | -33,977,000Source | -106,159,000Source | -61,661,000Source | -75,968,000Source | -46,833,000Source | -141,202,000Source | -122,526,000Source | -89,620,000Source | -51,321,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -33,977,000Source | — | — | — | — | — | — | -89,620,000Source | -52,836,000Source |
| Operating ExpensesUSD | — | — | 73,787,000Source | 45,836,000Source | 118,630,000Source | 70,451,000Source | 89,379,000Source | 56,311,000Source | 176,560,000Source | 158,228,000Source | 102,775,000Source | 52,561,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 514,573,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 869,000Source | 965,000Source | 4,525,000Source | 1,854,000Source | 800,000Source | 33,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -73,787,000Source | -45,836,000Source | -118,630,000Source | -70,451,000Source | -89,379,000Source | -56,311,000Source | -176,560,000Source | -158,228,000Source | -102,775,000Source | -52,561,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -65,604,000Source | -33,885,000Source | -105,925,000Source | -61,522,000Source | -75,778,000Source | -46,735,000Source | -140,687,000Source | -122,216,000Source | -89,384,000Source | -51,304,000Source |
| Income Tax Expense (Benefit)USD | — | — | 108,000Source | 92,000Source | 234,000Source | 139,000Source | 190,000Source | 98,000Source | 515,000Source | 310,000Source | 236,000Source | 17,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -65,712,000Source | -33,977,000Source | -106,159,000Source | -61,661,000Source | -75,968,000Source | -46,833,000Source | -141,202,000Source | -122,526,000Source | -89,620,000Source | -51,321,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.37Source | -0.2Source | -0.49Source | -0.36Source | -0.35Source | -0.27Source | -0.8Source | -0.78Source | -0.81Source | -5.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.37Source | -0.2Source | -0.49Source | -0.36Source | -0.35Source | -0.27Source | -0.8Source | -0.78Source | -0.81Source | -5.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 175,469,000Source | 171,630,000Source | 217,957,000Source | 172,647,000Source | 217,326,000Source | 172,051,000Source | 177,596,000Source | 157,922,000Source | 110,198,000Source | 9,584,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 175,469,000Source | 171,630,000Source | 217,957,000Source | 172,647,000Source | 217,326,000Source | 172,051,000Source | 177,596,000Source | 157,922,000Source | 110,198,000Source | 9,584,000Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 436,000Source | 328,000Source | 222,000Source | 77,000Source |
| General and Administrative ExpenseUSD | — | — | 14,798,000Source | 13,238,000Source | 18,573,000Source | 15,741,000Source | 22,872,000Source | 13,444,000Source | 61,554,000Source | 49,414,000Source | 32,672,000Source | 16,368,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -144,077,000Source | -113,107,000Source | -79,895,000Source | -44,258,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -33,977,000Source | — | — | — | — | — | — | -89,620,000Source | -52,836,000Source |
| Operating ExpensesUSD | — | — | 73,787,000Source | 45,836,000Source | 118,630,000Source | 70,451,000Source | 89,379,000Source | 56,311,000Source | 176,560,000Source | 158,228,000Source | 102,775,000Source | 52,561,000Source |
| Research and Development ExpenseUSD | — | — | 58,989,000Source | 32,598,000Source | 100,057,000Source | 54,710,000Source | 66,507,000Source | 42,867,000Source | 225,255,000Source | 108,814,000Source | 70,103,000Source | 36,193,000Source |
Filing attachments
tm2624945d1_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 tm2624945d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Ph…
Read attachment ↗tm2624945d1_ex99-2.htm · 8-K · 2026-09-08
EX-99.2 3 tm2624945d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1 Amylin and GLP - 1 Program Updates September 8, 2026 2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward - looking statements, including, without limitation, statements concerning: the e stimated addressable patient …
Read attachment ↗tm2622407d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622407d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on track for Q3 2026 Topline 72-week aleniglipron …
Read attachment ↗tm2613721d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 4 tm2613721d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the Body Composition and Type 2 Diabetes / Obesity…
Read attachment ↗tm2611763d1_ex99-1.htm · 8-K · 2026-04-15
EX-99.1 2 tm2611763d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel SAN FRANCISCO, April 14, 2026 - Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang …
Read attachment ↗